HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $19.
Stocks · News reference
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.
Full Transcript: AngioDynamics Q4 2026 Earnings Call
AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial
8-K filing — ANGIODYNAMICS INC (ANGO)
Filed: 2026-07-14 AccNo: 0001140361-26-028368 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits